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Antiviral CD8+ T cells respond to only aminute fraction
of the potential peptide determinants encoded by viral
genomes. Immunogenic determinants can be ordered
into highly reproducible hierarchies based on the
magnitude of cognate CD8+ T cell responses. Until re-
cently, this phenomenon, termed immunodominance,
was largely defined and characterized in model sys-
tems utilizing a few strains of inbred mice infected
with a handful of viruses with limited coding capacity.
Here, I review work that has extended immunodomi-
nance studies to viruses of greater complexity and to
the real world of human antiviral immunity.
Introduction
Make everything as simple as possible, but not
simpler.
—Albert Einstein
CD8+ T cells play an increasingly well-documented
role in clearing virus infections. There is mounting inter-
est in designing preventive and therapeutic vaccines ca-
pable of eliciting or enhancing virus-specific CD8+ T cell
responses. It is hoped that such vaccines will prove
useful for infections with both persistent (e.g., human
immunodeficiency virus [HIV]) and acute (e.g., influenza
A virus [IAV]) infections that are poorly controlled by
standard vaccine approaches.
Antiviral CD8+ T cells recognize virus-encoded pep-
tides bound to major histocompatibility complex (MHC)
class I molecules. Viral peptides, typically eight to ten
residues in length, are predominantly generated from
viral gene products through the initial action of pro-
teasomes followed by trimming via aminopeptidases
(Saveanu et al., 2005; Strehl et al., 2005). Proteasomes
act either on antigen synthesized by the antigen-
presenting cell (APC) (termed direct presentation) or
on antigens acquired by the APC (cross-presentation).
Viruses encode between a few thousand and tens of
thousands of amino acids, and therefore potentially
encode equivalent numbers of potentially immunogenic
peptides. Remarkably, the bulk of responding CD8+
T cells recognize a tiny fraction of potential determi-
nants, whose identities are governed by the MHC class
I allomorphs expressed by the responding individual.
(Allomorphs are the collection, present in any given ver-
tebrate species, of class I alleles encoded by two or
three class I loci; humans and mice have three such
loci: HLA-A, -B, and -C, and H-2-K, -D, and -L, respec-
tively.) This phenomenon, first described for CD4+ T
cells, is termed immunodominance (Sercarz et al.,
*Correspondence: jyewdell@nih.gov1993). ‘‘Immunodominant’’ determinants (IDDs) are rec-
ognized by the most abundant cognate T cell popula-
tions, whereas ‘‘subdominant’’ determinants are recog-
nized by less abundant T cell populations. Antiviral
responses to immunodominant and subdominant deter-
minants form a hierarchy (a-, b-, etc.) that is remarkably
reproducible between individuals of a given inbred
mouse strain. It is important to note that immunogenicity
is strictly an operational term and is limited by the tech-
nology available for detecting responses to potential
determinants above background values (>1/2000 and
>1/50,000 of total CD8+ T cells via flow-based and
ELISPOT methods, respectively). It is (and always will
be) impossible to definitively eliminate the possibility
that a given determinant is immunogenic. Thus, any im-
munodominance hierarchy will be, to a greater or lesser
extent, an oversimplification of reality.
Immunodominance reflects the final product of multi-
tudinous positive and negative factors that govern
antigen presentation and T cell activation (Yewdell and
Bennink, 1999). In the broadest terms, this breaks
down into two categories, each with numerous sub-
categories:
(1) Abundance of peptide class I complexes on affer-
ent APCs (i.e., APCs that activate antiviral CD8+
T cells, typically dendritic cells, but probably
other cell types as well [Pozzi et al., 2005]).
(2) Numbers of naive T cells with complementary
T cell receptors (TCRs) that access afferent
APCs and their capacity to proliferate and gener-
ate primary effector and memory CD8+ T cells.
More than 90% of immunodominance can be ex-
plained by the finding that only w1% of peptides bind
with sufficient affinity to a given class I allomorph to
form a complex of sufficient stability to be presented
in adequate numbers to activate naive CD8+ T cells. Bio-
informatic analysis (Istrail et al., 2004) predicts that this
low fraction of class I binding peptides applies to all
organisms (includingMethanococcus jannaschii, the ex-
tremophile that lives in deep ocean vents and is unlikely
to have encountered the vertebrate MHC in its evolution)
and does not reflect evolutionary pressure to avoid (or
enhance) immune recognition. Rather, the class I bind-
ing groove simply appears to have evolved to bind a
low fraction of peptides.
Although class I binding selectivity narrows the pep-
tide repertoire considerably, it still leaves thousands of
viral peptides for the immune system to potentially
choose among (Figure 1). Studying how and why these
choices are made and their consequences for immune
function is the basis of current immunodominance stud-
ies. Understanding immunodominance is part and par-
cel of understanding the MHC class I-CD8+ T cell immu-
nosurveillance system itself. Practically speaking, a
thorough understanding of immunodominance is re-
quired to rationally design vaccines that elicit CD8+ T
cell responses to defined determinants with sufficiently
broad specificity to avoid selecting viral escape
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534variants. Readers are directed to a comprehensive re-
view of immunodominance in antiviral CD8+ T cell re-
sponses for a broad discussion of the phenomenon
and contributing factors (Yewdell and Bennink, 1999).
In addition, there are a number of excellent more recent
reviews that provide detailed information on specific
factors that contribute to immunodominance or focus
on factors that contribute to immunodominance to spe-
cific viruses (Crowe and Woodland, 2006; Gaddis et al.,
2006; Kedl et al., 2003; Landais et al., 2005; Lichterfeld
et al., 2005; Maini and Bertoletti, 2006; Munks and Hill,
2006; Sette and Fikes, 2003; Sette and Sundaram,
2006; Tscharke and Suhrbier, 2005; Welsh, 2006; Whit-
ton et al., 2004; Yewdell and Del Val, 2004; Yewdell
Figure 1. E Pluribus Pauci: Filters that Contribute to Immunodomi-
nance
Vaccinia virus, the prototypical poxvirus, encodes w58,000 amino
acids that can potentially generate greater than 175,000 8 mer, 9
mer, or 10 mer peptides presented by class I molecules (‘‘greater
than’’ because of potential alternative reading-frame peptides and
peptides with posttranslational modifications). These are winnowed
down intow50 determinants that appear account for > 90% of the
CD8+ T cell response in B6 mice infected with vaccinia virus (Mou-
taftsi et al., 2006). Current knowledge (Yewdell and Bennink, 1999)
suggests that only 20% of these peptides can be liberated in immu-
nogenic quantities by proteasomes working in cahoots with other
cytosolic and ER proteases. TAP functions to transport cytosolic
peptides into the ER and exhibits a preference for transporting the
types of peptides preferred by the allomorphs expressed by a given
species. The net effect is that TAP has little selective effect on immu-
nodominance, which is mainly governed by class I binding. Each
class I allomorph binds on the order of 1% of potential peptides
with sufficient stability to trigger ER export. The TCR repertoire is
sufficiently diverse to recognize w50% of the peptide class I com-
plexes generated as a result of central and peripheral tolerance
and perhaps innate holes in the repertoire as well. Immunodomina-
tion, the suppression of responses to subdominant determinants by
immunodominant determinants, accentuates the hierarchy, but this
effect varies greatly in magnitude on a system-specific basis.and Haeryfar, 2005). The present review highlights re-
cent advances in defining and understanding immuno-
dominance in antiviral CD8+ T cell responses to complex
viruses in mice and in extending this knowledge to
human antiviral responses.
Complexity of Responses to Complex Viruses
Until recently, studies on immunodominance largely fo-
cused on viruses with a relatively limited coding capac-
ity: IAV and lymphocytic choriomeningitis virus (LCMV)
infections in mouse model systems and HIV infections
in humans. Exploiting technical advances, particularly
those that have lowered the costs of peptide synthesis,
viral immunologists are now tackling the problem of
defining immunodominance in CD8+ T cell responses
to viruses with large genomes. Table 1 summarizes
the strengths and weaknesses of the four major ap-
proaches that have been used for determinant discovery
(the fifth approach is being developed by a number of
laboratories).
Poxviruses
Poxviruses are among the largest viruses to infect hu-
mans, with a genome capable of encoding w60,000
amino acids in 258 predicted open reading frames
(ORFs). Tscharke et al. (2005, 2006) used a cDNA library
encoding all of the annotated vaccinia virus (VV) ORFs to
identify target-gene products, finding that in both H-2d
and H-2b mice a handful of determinants account for
about half of the total anti-VV response, with a single de-
terminant accounting for approximately a quarter of the
total response following intraperitoneal infection. The
degree of dominance of the a-determinant was depen-
dent on the route of immunization, with this determinant
accounting for roughly half of the total response follow-
ing intradermal infection, the route used for human
vaccination. This appears to be the first published
observation relating the route of viral immunization to
the immunodominance hierarchy, which is surprising,
given that this is potentially of great importance for
vaccination.
Jing et al. (2005) used a random-expression library
consisting of 3 3 104 unique colonies expressing
w300 bp fragments of VV genomic DNA (w50-fold
over sampling of the VV genome) to characterize the
specificity of CD8+ T cells from VV-vaccinated patients.
This approach confers the advantage of immediately
confirming specificity by obtaining multiple independent
hits with clones expressing overlapping fragments (it
also provides a relatively short sequence for identifying
the relevant antigenic peptide—like shooting peptides in
a barrel). Including all clones and bulk cultures studied
from eight individuals, determinants in 15 different VV
gene products were identified. Interestingly, 10 of these
gene products are known to be expressed early in the in-
fectious cycle (i.e., prior to DNA replication), whereas
only one is known to be a late gene product (the other
four are undefined).
Sette and colleagues used a 2,256 member library of
peptides predicted by computer algorithms to bind
with high affinity to Kb or Db to characterize the
C57BL/6 mouse immunodominance hierarchy to VV
(Moutaftsi et al., 2006). Forty-nine peptides were anti-
genic, including all of the five identified by Tscharke
et al. (2005). All 49 antigenic peptides demonstrated
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peptides
In developmenta dissociation constant (KD) for class I of less than
2.6 mM (note that a lower dissociation constant means
higher-affinity binding), with 66% of the peptides bind-
ing with very high affinity (KD < 20 nM). Nearly 80% of
the antigenic peptides scored in the top 300 in terms
of in silico predicted binding, with all antigenic peptides
present in the top 500 (welcome news, surely, for labora-
tories with more limited budgets for purchasing pep-
tides). Altogether, the 49 peptides appeared to account
for nearly the entire anti-VV response measured using
VV-infected APCs as global VV-specific CD8+ T cell
activators. The a-determinant identified by Tscharke
et al. (2005) accounted for 25% of the total response,
with 50% and 75% of the total response accounted for
by the top three and six peptides, respectively. Determi-
nants were preferentially derived from viral proteins of
greater than 100 residues and from those synthesized
early in the infectious cycle.
Team Sette used an even larger synthetic-peptide
library, composed of more than 6000 VV-encoded se-
quences predicted in silico to bind to the five most prev-
alent HLA-A and -B supertypes to measure CD8+ T cell
specificity induced by standard smallpox vaccination
(i.e., live VV introduced intradermally) of 58 volunteers
with disparate HLA types (Oseroff et al., 2005). Of the
53 antigenic peptides identified, 52 demonstrated a KD
of < 500 nM with the relevant HLA allomorph. Thirty-
five different ORFs were recognized. Consistent with
the findings of Jing et al. (2005), early gene products
were overrepresented by more than 5-fold. The bias
toward early gene products may be even greater than
appears, because ‘‘late’’ genes may actually be ex-
pressed in small quantities prior to DNA replication.Many of the late proteins are viral structural proteins.
Of 30 known virion proteins, only one was antigenic,
suggesting that virions themselves are weak immuno-
gens. The preferential immunogenicity of early viral pro-
teins suggests that priming of VV responses is largely
based on dendritic cell (DC) presentation of endogenous
viral proteins (Norbury et al., 2002). This would be con-
sistent with the reported block in late gene expression
in VV-infected DCs (Bronte et al., 1997).
Contrasting with mouse systems, Oseroff et al. (2005)
found that the human anti-VV response was relatively
‘‘immunodemocratic,’’ i.e., responses were equally dis-
tributed among determinants. Further, individual deter-
minants recognized by individuals could not be pre-
dicted simply on the basis of their HLA genotype,
echoing previous findings with HIV specific CD8+ T cells
(Betts et al., 2000). Insight into this phenomenon comes
from VV-specific CD8+ T cell responses in HLA trans-
genic mice (Pasquetto et al., 2005), where the HLA-
restricted immunodominance hierarchy was influenced
by the presence or absence of endogenous mouse
class I genes. Thus, in humans, the antiviral repertoire
restricted by a given class I allomorph may be heavily
influenced in some circumstances by the other class I
allomorphs expressed by a given individual.
Studies in mouse model systems have demonstrated
such interallomorphic influences on immunodominance
hierarchies (Belz et al., [2000] and see below), but this is
not a universal finding. Immunodominance hierarchies to
IAV meld fairly smoothly when responses in F1 and pa-
rental mice are compared (Belz et al., 2000; Chen et al.,
2002), and knocking out single class I genes was found
to have little effect on the acute immunodominance
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536hierarchy to LCMV (van der Most et al., 2003). In humans,
immunodominant responses to individual viral deter-
minants can also be largely controlled by expression of
the restricting HLA allomorph (Yu et al., 2002). This phe-
nomenon is well known to human cellular immunologists
who use an immunodominant HLA-A2-restricted pep-
tide from IAV or cytomegalovirus (CMV) as positive con-
trols in A2-positive volunteers (but, as discussed below,
these determinants may be exceptional in being recog-
nized by highly conserved TCRs).
Herpesviruses
Unlike VV, which causes an acute infection and is
cleared relatively rapidly, herpesviruses, which include
CMV, herpes simplex virus (HSV), and Epstein-Barr virus
(EBV), generally cause life-long infections. During their
long coevolution with their vertebrate hosts, herpes-
viruses devised numerous stealth strategies for avoid-
ing immune detection, including limiting their gene ex-
pression to the bare minimum (latency) and directly
impeding CD8+ T cell surveillance by expressing viral
genes that interfere with antigen presentation (VIPRs).
The contribution of these virus life-style strategies to
the composition of immunodominance hierarchies is
one of the more interesting aspects of the CD8+ T cell
responses to herpesviruses.
Cytomegalovirus. Munks et al. (2006) used a DNA li-
brary encoding all 170 predicted murine CMV (MCMV)
ORFs (encodingw70,000 amino acids) to identify deter-
minants recognized by C57BL/6 mice. Herpesviruses
are, in general, highly host specific, but MCMV provides
an excellent model for human CMV (HCMV) infections.
During a primary infection, CD8+ T cell responses to 27
distinct gene products were detected. Responses to
a single determinant accounted forw25% of the overall
response, with the top four peptides in the hierarchy ac-
counting for w50% of the response. Using H-2b or F1
mice with different background genes, Munks et al.
(2006) found that although the most immunodominant
determinants retained their spots atop hierarchy, some
shuffling was evident. Importantly, this indicates that
non-MHC genes can influence the immunodominance
hierarchy, and it represents another factor contributing
to variation in human antiviral immunodominance hierar-
chies among individuals sharing identical HLA alleles.
It will be of great interest to determine the influence of
MCMV VIPRs on this complex immunodominance hier-
archy, particularly in light of previous evidence that
although deletion of three VIPRs from the viral genome
greatly impacts antigen presentation in vitro, it has little
affect on the magnitude of overall anti-MCMV CD8+
T cell responses in vivo (Gold et al., 2002). The effect
of VIPRs on viral immunogenicity has been used as
a means of gauging the contributions of direct versus
cross-priming of antiviral CD8+ T cell responses, the as-
sumption being that VIPRs should act only in cells that
express them, and therefore should exclusively inhibit
direct priming (Basta et al., 2002; Shen et al., 2002). If
this assumption is correct, it implies that VIPRs function
to conceal virus-infected cells from efferent CD8+ T
cells, thereby facilitating virus replication and ultimately
transmission between hosts. Lu et al. (2006) provide the
initial evidence that the MCVM VIPRs indeed serve this
function. The capacity of MCMV to serve as a persistent
recombinant vaccine that induces strong and graduallyexpanding CD8+ T cell responses to inserted genes
(Karrer et al., 2004) is presumably based on persistent
cross-presentation enabled by this VIPR-mediated con-
cealment of infected cells. This exceptionally promising
finding suggests a novel vaccine strategy for maintain-
ing strong CD8+ T cell responses, a strategy that could
be an essential feature for a prophylactic HIV vaccine
or for vaccines that maintain consistently high numbers
of anti-influenza CD8+ T cells.
To understand immunodominance to HCMV, Syl-
wester et al. (2005) performed the tour de force of deter-
minant-mapping studies. Using a 13,687-strong panel of
synthetic peptides representing overlapping 15 mer
peptides covering the entire HCMV genome encoding
213 predicted ORFs, they determined the anti-HCMV
specificities of CD8+ T cells (and CD4+ T cells) in periph-
eral blood mononuclear cells (PBMCs) from 33 seropos-
itive patients. Remarkably w5% of total circulating
CD8+ T cells recognize HCMV determinants. From 33
individuals examined, CD8+ T cells recognized determi-
nants present in 107 ORFs, representing all known func-
tional and kinetic classes of viral proteins (i.e., early ver-
sus late expression). Individual seropositive patients
responded to an average of eight ORFs, with a high of
32 and a low of a single ORF recognized, and an average
magnitude of 0.5% of total CD8+ T cells responding to
each ORF recognized.
Though individual immediate early (IE) proteins (the
very first proteins expressed in herpesvirus-infected
cells) had a moderately greater statistical chance of im-
munogenicity per residue of protein encoded, nearly
90% of the response was directed to proteins synthe-
sized later in infection. Because HCMV VIPRs are ex-
pressed after IE genes, this suggests that the VIPRs
have at most only a minor impact on immunogenicity
of HCMV gene products, consistent with previous find-
ings made at the level of overall virus-specific responses
(Manley et al., 2004). Ironically, for VV, which lacks
VIPRs, human (but not mouse) responses appear to fo-
cus on early viral-gene products, pointing out how
quirks in each virus-host relationship can influence the
nature of CD8+ T cell targets.
Sylwester et al. (2005) did not determine the HLA re-
striction of individual determinants, so interallomorphic
and extra class I genetic effects on the immunodomi-
nance hierarchy await further detailed investigation.
Interestingly, the one pair of seropositive twins studied
responded nearly identically to the panel of peptides,
extending similar findings with anti-HIV responses ob-
served in two sets of twins (Draenert et al., 2006; Yang
et al., 2005). Twins are nearly the human genetic equiv-
alent of A3 B F1 mice (but not truly equivalent because,
unlike inbred mice, all humans have some recessive
lethal genes, in addition to lacking other genetic alter-
ations associated with inbreeding), so these findings
(though limited in scope) support the validity of the
mouse model for studies of immunodominance in
human antiviral responses.
HSV. Hosken et al. (2006) used a panel of 4968 over-
lapping 15 mer peptides to study CD8+ T cell responses
to 48 herpes simplex virus 2 (HSV2) ORFs in 37 seropos-
itive individuals. Each ORF examined was recognized by
at least one patient in the study. Individuals responded
to determinants from as few as three ORFs or as many as
Review
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IE proteins were preferred targets, late proteins were
also recognized.
This broad human anti-HSV2 response stands in stark
contrast to the anti-HSV1 response in C57BL/6 mice,
where up to 90% of primary CD8+ T cells recognize a
single determinant in glycoprotein B (gB) (Wallace
et al., 1999). Compromising the CD8+ T cell response
to this one determinant increases viral pathogenicity,
indicating that functional responses to other determi-
nants cannot replace the antiviral activity exerted by
gB-specific CD8+ T cells (Messaoudi et al., 2002). This
is reminiscent of the observation by Rosenthal and
Zinkernagel (1981) that despite encoding 3536 amino
acids, vesicular stomatitis fails to elicit a detectable
H-2k restricted cytotoxic response in mice (the virus is
highly immunogenic in H-2b or H-2d mice). Certain com-
binations of individual MHC allomorphs and viruses
seem to result in highly limited CD8+ T cell responses
that beg explanation, exposing a significant gap in our
understanding of immunodominance.
EBV. Brander and colleagues studied CD8+ T cell re-
sponses to EBV in 40 acutely or chronically infected in-
dividuals by using a panel of 80 optimally sized peptides
with previously defined antigenicity and restriction ele-
ments (Woodberry et al., 2005). Notably, they found ‘‘un-
expected’’ responses in no less than 72% of individuals
who lacked the expected HLA allele (the extent to which
this reflects ‘‘promiscuity’’ as concluded versus spuri-
ous cross-reactivity due to the use of peptides at
10 mM for CD8+ T cell activation [at least 4 logs higher
than should be necessary] remains to be determined).
Acutely infected individuals responded on average to
three determinants increasing to five determinants in
chronic infections. These are minimal estimates be-
cause of the limited size of the peptide pools used,
which covers a relatively small fraction of the EBV pro-
teome. The study included four siblings with identical
HLA types. Response to individual determinants be-
tween siblings was highly similar, but not identical.
Brander’s laboratory extended this approach to in-
clude a panel of 184 HIV determinants and examined
the influence of EBV coinfection on HIV responses and
HIV coinfection on EBV responses (Bihl et al., 2006).
They used three patient sets: patients infected with
HIV only, patients infected with EBV only, and patients
infected with both viruses. This analysis provides a num-
ber of important insights into immunodominance in
humans:
(1) HIV coinfection (whether treated with antiretro-
viral drugs or not) did not greatly influence the
magnitude or composition of the EBV response.
(2) There was a good correlation between the mag-
nitude of responses to individual HIV or EBV
determinants and the frequency of responses to
determinants in individuals with the appropriate
restricting HLA allomorph. As a corollary, re-
sponses to HLA-B-restricted determinants were
the most robust and the most prevalent. The
dominance of HLA-B in antiviral responses over
HLA-A and particularly HLA-C (which appears
to be used only infrequently) may extend to
other viruses. In a more limited study, HLA-Bwas preferentially recognized by CD8+ T cell pop-
ulations specific to polyclonal influenza A or B
virus (Boon et al., 2004). The how and, particu-
larly, the why of these HLA-locus-specific effects
in viral immunity remain an important mystery
(see dirty little secret #5 in [Yewdell, 2005]).
(3) Among defined EBV or HIV determinants, the af-
finity of synthetic peptides for class I with a given
class I allomorph did not closely correlate with
the magnitude or frequency of responses to the
determinant. This is somewhat surprising, be-
cause all things being equal, peptide affinity
must affect the number of peptide-class I com-
plexes available for activation of naive and mem-
ory CD8+ T cells. Although the processes of pep-
tide generation and delivery also are major
variables in controlling complex number, this
should average out with a large enough data set
to reveal a contribution of peptide affinity. The
data set may simply be too small for the relation-
ship between affinity and immunogenicity to be
clear. Alternatively, the measured affinity of syn-
thetic peptides for purified class I molecules or
peptide-receptive cell-surface class I molecules
may not accurately reflect the natural interaction
of peptides with class I molecules in APCs.
(4) There was no clear correlation between CD8+ T
cell sensitivity (i.e., the number of synthetic-pep-
tide-generated complexes needed for activation)
and the magnitude of responses to given HIV or
EBV determinants. This finding is consistent
with previous studies that have failed to closely
correlate the immunodominance hierarchy or
the sensitivity of responding CD8+ T cells with
numbers of complexes generated via the endog-
enous pathway (Chen et al., 2000; Crotzer et al.,
2000), although exceptions have been reported
(Fu et al., 1998; Restifo et al., 1995; Wherry
et al., 1999). It seems that for many, though not
all, determinants, endogenous presentation in
vivo reaches sufficient levels to achieve near-
maximal activation of their cognate CD8+ T cell.
Man versus Mouse
The patient studies described above demonstrate that
immunodominance hierarchies exist in human antiviral
responses but, compared to mouse model systems, ap-
pear to be more immunodemocratic and less predict-
able. Although the mouse systems utilized may not be
perfect models for human antiviral responses, clearly
they provide a useful knowledge base that enables for-
mulation of hypotheses of great value in understanding
human responses.
A number of factors probably contribute to the greater
variability of real-world immunodominance hierarchies
in human antiviral responses.
First, mice are infected in a given experiment with the
same virus, at the same dose, and via the same route.
Even DNA viruses, which exhibit much less variability
than RNA viruses (particularly HIV), exhibit significant
variation between strains that circulate in human popula-
tions. Amino acid substitutions potentially affect immu-
nogenicity by altering either determinants themselves
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Other substitutions could affect viral tropism or other
parameters of replication that alter antigen presentation
to CD8+ T cells. Viral dose does not seem to have a sig-
nificant influence on immunodominance hierarchies,
but probably only because this has not been studied
with sufficient zeal. Likewise, little is known about the
influence of the route of infection, although, as cited
above, it does affect the immunodominance hierarchy
in the mouse anti-VV response (Tscharke et al., 2005).
Second, humans exhibit a great number of genetic dif-
ferences outside of the MHC that potentially affect anti-
gen presentation and T cell activation. Genes encoding
transporter associated with antigen processing 1 (TAP1)
and TAP2 exhibit polymorphism that may alter the pre-
sented peptide repertoire (Kjer-Nielsen et al., 2004).
Class I allomorphs can affect each other’s function by
immunodomination, in which CD8+ T cells specific for
IDDs suppress responses to subdominant determinants
(reviewed in (Kedl et al., 2003) or by altering the TCR rep-
ertoire via tolerance mechanisms (Burrows et al., 1995).
Tolerance to polymorphic self-minor histocompatibility
antigens can also sculpt the TCR repertoire. Polymor-
phic differences in genes involved in T cell-APC inter-
actions or controlling viral replication could influence
the immunodominance hierarchy. Detailed mapping in
H-2b mice of the genetic differences in background
genes leading to the alterations in the immunodomi-
nance hierarchy to MCMV (Munks et al., 2006) might
shed considerable light on the contribution of non-
MHC genes to immunodominance, an area of woeful
ignorance.
Third, whereas humans experience frequent encoun-
ters with extraneous viral and other infectious agents
and antigens, no efforts are spared to protect mice
from exposure to microbial agents save the normal com-
mensal epithelial organisms. On the basis of the sizable
ratio of the universe of possible foreign antigens versus
the number of TCRs that constitute the CD8+ T cell rep-
ertoire, it has been argued that TCR recognition should
be highly degenerate (Mason, 1998). On the other
hand, a compelling case has been made that the proba-
bility of cross-reaction of a given TCR with any given
peptide determinant is miniscule, on the order of 1027
(Borghans and De Boer, 1998). Still, with an antiviral re-
sponse composed of 104 to 105 specificities, and 101 to
103 viral determinants presented by class I molecules for
potential cross-reactive recognition, some cross-reac-
tive recognition appears to be possible, if not likely.
Heterologous Immunity: A Critical Appraisal
Ballpark numbers generated by theory are interesting
(and fun), but ultimately, reality counts. Welsh, Selin,
and colleagues have extensively studied the influence
of prior viral exposure on subsequent mouse responses
to heterologous infection (Welsh, 2006; Welsh and Selin,
2002; Welsh et al., 2004). They have shown that re-
sponses to a determinant in LCMV NP are enhanced
by prior infection of mice by Pinchinde virus, a different
arenavirus (Brehm et al., 2002; Kim et al., 2005). The ho-
mologous determinants in the two viruses are identical
at six of eight positions. Moreover, the source proteins
are 69% homologous, so this cross-reaction is not
a bolt out of the blue. It has been shown in numeroussystems that memory T cells suppress responses by
naive T cells (Jamieson and Ahmed, 1989) (one form of
immunodomination), providing a general mechanistic
explanation for the Pichinde-virus-induced alteration in
the LCMV ID hierarchy.
More interesting are Welsh and Selin’s examples of
cross-reactivity between peptides from unrelated vi-
ruses (Urbani et al., 2005; Wedemeyer et al., 2001). The
most thorough mechanistic exploration of the phenom-
enon comes from Kim et al. (2005), who showed that VV
infection of C57BL/6 mice previously infected with
LCMV resulted in the selective expansion of CD8+ T cells
specific for distinct LCMV determinants. Despite being
inbred, individual mice demonstrated great variation in
the specificities of memory LCMV CD8+ T cells ex-
panded by VV infection. Adoptive transfer of CD8+ T
cell populations from individual LCMV-primed mice
into recipients then infected with VV provided an elegant
demonstration that this was due to differences in the
anti-LCMV repertoires of individual mice and not to sto-
chastic factors associated with VV infection. A missing
piece of this puzzle, however, is the identity of the
cross-reactive antigens in VV that expand the corre-
sponding LCMV populations. A candidate VV peptide
proposed by Kim et al. (2005) to account for expansion
of one of the LCMV populations was tested by Moutaftsi
et al. (2006) and was not antigenic (the antigenicity ob-
served by Kim et al. may be an artifact of using the VV
peptide at high concentrations [5 mg/ml] for stimulation).
Importantly, the antigenicity of synthetic viral peptides is
not equivalent to the immunogenicity of the actual deter-
minant in the context of a viral infection. Nonimmuno-
genic ‘‘mimotopes’’ have been described (Belz et al.,
2001) that cross-react with true determinants in the
same virus, even though the determinants are remark-
ably divergent in sequence (ISPLMVAYM versus
SSYRRPVGI; a result that should give pause to those
attempting to identify cross-reactions on the basis of se-
quence homology!). Ultimately, demonstrating true het-
erologous immunity will entail knocking out putative
cross-reactive determinants in priming and challenge
viruses and showing that this eliminates enhancement
attributed to heterologous immunity.
Despite these caveats, Welsh and Selin’s findings
provide important insight into the phenomenon of heter-
ologous immunity, particularly in demonstrating that
cross-reactions are likely to vary on the basis of private
specificities that arise via stochastic events in the gener-
ation of TCR repertoires in individuals (Welsh, 2006).
With the additional genetic differences present in out-
bred human populations in MHC and non-MHC genes,
heterologous immunity in human responses is predicted
to vary considerably between individuals.
With the constant exposure of humans to viruses (typ-
ically a total of w10 subclinical and clinical infections
per year per individual), it would be expected that
individuals would possess memory CD8+ T cells that
cross-recognize determinants from previously unen-
countered viruses, particularly viruses with large coding
capacity. Yet Oseroff et al. (2005) failed to detect recog-
nition of any of the >6000 VV-encoded peptides by PBLs
from patients prior to immunization. Likewise, Sylwester
et al. (2005) found that PMBC from six of ten patients
seronegative for HCMV failed to recognize any of the
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patients, two recognized peptides from a single gene
product, and two patients recognized two or three gene
products. Similarly, Hosken et al. (2006) found very lim-
ited recognition of HSV-2 peptides by two seronegative
patients.
Thus, although the jury is still out, it appears that
cross-recognition in humans may occur less frequently
than predicted by mouse studies.
Specificity and Function
One of the most important, yet least studied aspects of
the relationship between immunodominance and immu-
nity is the influence of CD8+ T cell specificity for individ-
ual viral determinants on their antiviral activity in vivo.
This information is critical to designing defined determi-
nant-based vaccines. Specificity could potentially influ-
ence CD8+ T cell function by either quantitative or qual-
itative effects. Obviously, one important factor in the
specificity-function relationship is the magnitude of
responses to individual determinants: Up to a certain
point, more responding CD8+ T cells should exert more
antiviral activity. At one extreme of the response spec-
trum are naturally processed and presented determi-
nants that are unable to elicit detectable CD8+ T cells
because of deficiencies in the CD8+ T cell repertoire,
i.e., there are no suitable clones capable of responding
(Yewdell and Bennink, 1999). No doubt, more subtle dif-
ferences in precursor numbers to naturally processed
determinants will lead to parallel differences in respond-
ing CD8+ T cell numbers and antiviral activity. Although
this has yet to be demonstrated experimentally, Choi
et al. (2002)and La Grutaet al. (2006) established, respec-
tively, a direct relationship between precursor frequency
and immunodominance in minor histocompatibility anti-
gen responses and secondary anti-IAV responses.
It is also predictable that determinant-specific differ-
ences in antigen presentation by infected target cells
will result in differences in antiviral activity of the cog-
nate CD8+ T cell clones. For example, CD8+ T cells spe-
cific for late viral antigens should, on average, exert less
antiviral activity against infected cells than early-anti-
gen-specific CD8+ T cells, given a virus that produces in-
fectious progeny within a few hours of turning on late
viral genes (typically, viral structural proteins are en-
coded by late genes). Even among CD8+ T cells specific
for early antigens, CD8+ T cells specific for determinants
that are more abundant should, on average, recognize
target cells earlier and exert more potent antiviral activ-
ity. These factors probably contribute to the deter-
minant-dependent differences in antiviral activity of
HIV-specific CD8+ T cells (Ali et al., 2004; Yang et al.,
2003). Herpesviruses provide an extreme example of ki-
netic differences in target-antigen expression. Latently
infected cells that serve as a viral reservoir express
only a few viral proteins compared to lytically infected
cells (i.e., cells supporting a full-blown infectious cycle).
Evidence suggests that CD8+ T cells specific for latent
antigens exert more effective anti-CMV activity (Bunde
et al., 2005; Sacre et al., 2005).
Discrepancies in the determinant-generating abilities
of afferent APCs in activating CD8+ T cells versus effer-
ent APCs in serving as CD8+ T cell targets will also result
in determinant-based differences in CD8+ T cell effectorfunction (Crowe et al., 2005; Crowe et al., 2006; Crowe
et al., 2003). Such differences can arise from cross-
priming by DCs versus direct presentation by target
cells (Chen et al., 2004), or from differences in proteases
in DCs versus target cells (Chen et al., 2001; Ito et al.,
2006; York et al., 2006), particularly prior to target-cell
exposure to IFN-g, which induces many of the proteases
constitutively expressed by DCs.
In principle, peptide specificity can also influence the
qualities of responding CD8+ T cells. This could result
from the particular circumstances of the duration or an-
atomical location of antigen priming, or by the nature of
costimulatory signals delivered by the afferent APC.
Intrinsic features associated with the specific class
I-peptide complexes may result in consistent signaling
differences among heterogeneous CD8+ T cell clones.
This might particularly apply to determinants recog-
nized by CD8+ T cell populations with limited TCR het-
erogeneity, because TCR conservation should favor
functional uniformity. Such less diverse CD8+ T cell pop-
ulations may typically recognize ‘‘plain vanilla’’ peptides
(Davis, 2003), determinants whose residues available for
TCR interaction lack prominent side chains (Lehner
et al., 1995; Meijers et al., 2005; Moss et al., 1991; Stew-
art-Jones et al., 2003; Trautmann et al., 2005; Turner
et al., 2005). Indeed, Kjer-Nielsen et al. (2003) reported
that interaction of one such highly conserved TCR with
its cognate EBV IDD resulted in conformational alter-
ations transmitted to the TCR constant region that are
potentially capable of modifying TCR-mediated signal-
ing. Such determinant-specific alterations in signaling
need not be evident from structural studies using iso-
lated TCRs and class I-peptide complexes (Ely et al.,
2006), however, particularly if multiple TCRs engaging
cognate ligands interact with each other on the surface
of a responding T cell. As an alternative approach, deter-
minant-specific structural alterations in TCRs might be
inferred from differences in downstream signaling
events associated with activation of CD8+ T cell popula-
tions specific for different determinants.
Presumably, such differences in signaling would en-
able determinant-specific differences in CD8+ T cell
function, a topic ripe for detailed investigation. CD8+ T
cells are known to be capable of independently modu-
lating cytotoxicity and secretion of IFN-g and TNF-
a (Guidotti et al., 1996; Snyder-Cappione et al., 2006).
Determinant-based differences in the abilities of CD8+
T cells to modulate immunodomination, apparently in-
dependently of differential antigen presentation, have
been reported in mouse responses to IAV and LCMV
(Chen et al., 2000; Rodriguez et al., 2001) and may play
a key role in establishing immunodominance hierar-
chies. Whitton, Slifka, and colleagues also demon-
strated determinant-specific differences in the ratio of
IFN-g secretion to cytolytic activity in LCMV infections
(Rodriguez et al., 2001). Extending these findings, Liu
et al. (2004) reported that IDD-specific CD8+ T cells se-
crete IFN-g faster upon specific activation than CD8+ T
cells specific for subdominant determinants. This is
a key finding, because it could well account for immuno-
domination by IDD-specific CD8+ T cells (Rodriguez
et al., 2002). It would be of great interest to broaden
these findings to other virus systems in mice and to
human responses. mRNA expression profiling of CD8+
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(with MHC-tetramer technology) could provide a number
of further leads into potential determinant-specific dif-
ferences in antiviral CD8+ T cell functions.
Understanding the relationship between CD8+ T cell
specificity and function is particularly important in HIV,
where there is intriguing evidence that CD8+ T cells of
the ‘‘right’’ specificity can control HIV infection for de-
cades in ‘‘elite suppressors,’’ individuals able to main-
tain normal CD4+ T cell numbers and low levels of virus
in plasma without antiretroviral chemotherapy. A pio-
neering study showed that eleven of 13 such patients
expressed HLA-B57, orw10-fold higher than expected
from its overall frequency in the relevant population
(Migueles et al., 2000). This cannot be attributed to the
inability of targeted determinants to vary because of
structural constraints of the source proteins, given that
escape mutants clearly are selected (Bailey et al.,
2006). Still, it seems likely that the anti-HIV activity of
HLA-B57 is based on the properties of its peptide-
binding domain, because individuals with other HLA-B
alleles with similar peptide specificity demonstrate re-
sistance to HIV (though typically to a lesser extent than
elite suppressors) (Frahm et al., 2005). Attaining a de-
tailed understanding of this phenomenon should pro-
vide considerable insight into manipulating CD8+ T cell
responses to treat HIV infections and, more generally, il-
luminate that connection between CD8+ T cell specificity
and antiviral function
Future Prospects
The leap to mapping human CD8+ T cell responses to
large genome viruses represents an important milestone
in understanding immunodominance in the real world. A
bump, however, on the road to immunodominance en-
lightenment is the wholesale use of synthetic peptides
as antigenic mimics without supporting evidence for
the immunogenicity of the corresponding sequence in
the context of translated viral proteins (see dirty little se-
cret #1 in [Yewdell, 2005]). This problem becomes acute
when high-affinity peptides are used at high concentra-
tions, resulting in the generation of tens of thousands of
complexes per APC, which is 10- to 10,000-fold greater
than naturally generated complexes (Yewdell and Ben-
nink, 1999). The use of overlapping 15 mer peptides to
measure antigenicity may circumvent this problem
(though inadvertently), because the actual antigenic
peptides are generated only through the action of cell-
surface, secreted, and fetal bovine serum (FBS) prote-
ases in what is typically an inefficient process. On the
other hand, the generation of such a heterogeneous
mixture of peptides can only hamper reproducibility. Ad-
mittedly, demonstrating the immunogenicity of putative
determinants by genetic approaches entails a consider-
able effort for what will typically result in confirmation
and not discovery. Without this information, however,
it is possible to be seriously misled by putative deter-
minants that actually represent nonimmunogenic se-
quences that cross-react with CD8+ T cells specific for
other determinants in the same virus, or in a completely
different antigen. Such cross-reactions could result in
partial agonism or antagonism and might be largely
based on private specificities and therefore result in
the erroneous conclusion of individual-based differ-ences in immunodominance hierarchies. Inasmuch as
we will have to deal with a core group of medically im-
portant viruses for as long as Homo sapiens exists,
surely it is worth the effort to define determinants from
these viruses with a reasonable degree of rigor. Ulti-
mately, it will require mass spectroscopy to identify
the full repertoire—which likely includes peptides of
atypical lengths, usual and unusual posttranslational
modifications (e.g., peptide splicing), and unexpected
translation products—of viral peptides presented to
the immune system.
Indeed, at this point, there are no real remaining tech-
nical hurdles to generating torrents of precise data re-
garding the composition and complexity of human T
cell responses to medically relevant viruses. In com-
bination with continued advances in mouse immuno-
dominance model systems and structural studies on
the nature of TCR-class I interactions, these data should
provide insight into a number of important issues includ-
ing the following:
(1) The properties of viral proteins (size, stability,
time of expression in the virus life cycle, intracel-
lular localization, function) that influence their
immunogenicity and effectiveness as CD8+ T
cell targets.
(2) The influence of the route of infection or immuni-
zation on immunodominance hierarchies.
(3) The contribution of past exposure to other
viruses in generating primary CD8+ T cell immu-
nodominance hierarchies.
(4) The contributions of cross-recognition and allel-
ism in non-MHC genes (including TAP and TCR
genes) in generating immunodominance hierar-
chies.
(5) The relationship between peptide-MHC structure
and the repertoire of responding CD8+ T cell pop-
ulations, and more specifically, whether plain
vanilla and ‘‘chocolate chip cookie dough’’ pep-
tides are consistently recognized in a fundamen-
tally different manner.
(6) The relationship between CD8+ T cell specificity
and antiviral functionality, and particularly the
contribution of MHC class I locus- and allele-
related differences to the process.
Indeed, a thorough understanding of immunodomi-
nance is ultimately essential to understanding the evo-
lution of the MHC-CD8+ T cell immunosurveillance
system. Since Zinkernagel and Doherty’s discovery of
MHC-restricted recognition of virus by T cells, it has
been widely assumed that pathogen immunity is by far
the most powerful selection factor in MHC evolution
and is responsible for the remarkable polymorphism of
MHC class I (and class II) genes. Recent findings, how-
ever, raise the possibility that tumor surveillance and
mate selection exert powerful selection pressure on
MHC class I genes, perhaps even surpassing selection
exerted by pathogen immunity (Murgia et al., 2006;
Pearse and Swift, 2006; Slev et al., 2006). The practical
point is that functional compromises may have been
reached in evolution to optimize MHC functions in mul-
tiple tasks. This cautions against seeking perfection in
explaining every feature of immunodominance in CD8+
Review
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faults that cannot be improved without a concomitant
decrease in other tasks that MHC class I genes have
tackled in evolution.
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